Basic Colofac Information

• INN (International Nonproprietary Name): Mebeverine
• Brand Names Available in Australia: Colofac
• ATC Code: A03AA04
• Forms & Dosages: Tablets (135 mg)
• Manufacturers in Australia: Mylan Australia
• Registration Status in Australia: Prescription-only medicine
• OTC / Rx Classification: Prescription only

Critical Warnings & Restrictions

Colofac, known generically as mebeverine, is a medication used primarily for treating functional gastrointestinal disorders such as irritable bowel syndrome (IBS). However, specific caution is warranted for certain high-risk groups.

High-Risk Groups

Individuals over the age of 65, pregnant women, and those with chronic health conditions should exercise caution when using this medication. The elderly may experience increased sensitivity, making it essential to consult with a healthcare provider before starting treatment.

For pregnant women, while data is limited, it’s typically recommended to avoid medications unless absolutely necessary. Chronic illness patients should also evaluate with healthcare professionals for any potential interactions with their existing treatments.

Precautions and Recommendations

• Always consult with a doctor before starting Colofac if you belong to a high-risk category.
• Monitor for any unusual side effects, particularly when taking other medications.
• Keep a close watch on symptoms if you're managing a chronic condition.

Interaction With Activities

Colofac can affect physical and mental capabilities, particularly with side effects like dizziness and fatigue. These may impair your ability to drive or operate machinery safely.

Australian law mandates that individuals must not drive if impaired by medication.

Q&A — “Can I Drive After Taking It in Australia?”

The straightforward answer is to consult your healthcare provider. While potential side effects like dizziness are mild, they may still hinder driving ability.

Usage Basics

Colofac, primarily available as 135 mg tablets, is specifically recognised for treating IBS and other related gastrointestinal issues. It’s categorised as a synthetic anticholinergic agent under the ATC code A03AA04, designed to alleviate symptoms like abdominal pain and cramping.

In Australia, Colofac is registered as a prescription-only medicine with the Therapeutic Goods Administration (TGA), implying that it must be dispensed by a licensed pharmacist. It is vital for patients to follow professionals' directions for use to ensure safety and efficacy.

Dosing Guide

The recommended dosage for adults is typically one 135 mg tablet taken three times daily. Patients should be aware of their individual needs, especially those who are elderly or have liver or kidney impairments.

For children under 10, Colofac is generally not recommended due to insufficient safety data. Elderly patients can usually follow standard adult dosing, but caution is advised to minimise potential side effects. Those with hepatic or renal impairments should also be monitored closely.

Q&A — “What If I Miss a Dose?”

If you forget to take a dose, take it as soon as you remember unless it’s close to your next scheduled dose. Never double up on doses to compensate for a missed one to avoid any overdose risks.

Interaction Chart

Caution is advised regarding food and drink interactions. For instance, the consumption of alcohol may intensify certain side effects.

Common drug interactions include:

• Other medications that also affect gastrointestinal motility
• Drugs with sedative effects may interact, heightening risks associated with dizziness

Always consult with a healthcare provider to review your current medications before starting Colofac.

User Reports & Trends

Numerous Australian patients have shared their experiences on platforms like ProductReview, noting that Colofac has been beneficial in managing IBS symptoms. Common themes in patient feedback include effective relief from abdominal pain and minimal side effects when used as directed.

Access & Purchase Options

Colofac is widely available across major pharmacy chains in Australia, including Chemist Warehouse, Priceline, and TerryWhite. For those who prefer to shop online, many telehealth services provide the option to obtain prescriptions remotely. This allows patients to purchase Colofac conveniently without needing to visit a pharmacy in person.

Mechanism & Pharmacology

Mebeverine, the active ingredient in Colofac, plays a crucial role in managing gastrointestinal motility disorders. It primarily works by relaxing the smooth muscles of the gut. This action helps alleviate spasms and discomfort associated with conditions like Irritable Bowel Syndrome (IBS). The drug specifically targets spasms in the bowel, promoting smoother digestive function and reducing the pain linked to intestinal contractions.

From a clinical perspective, mebeverine is classified as a synthetic anticholinergic agent, falling under the ATC code A03AA04, which is designated for drugs treating functional gastrointestinal disorders. Unlike other antispasmodics, mebeverine’s unique mechanism does not exhibit systemic anticholinergic properties. This makes it suitable for patients who may experience adverse reactions to traditional anticholinergics.

Indications & Off-Label Uses

Colofac is primarily indicated for the management of conditions such as Irritable Bowel Syndrome (IBS) and non-specific gut spasms. Approved by the Australian Therapeutic Goods Administration (TGA), it is prescribed to relieve the symptoms of abdominal pain, cramping, and irregular bowel movements often experienced by patients suffering from IBS.

In Australian clinical practice, while the therapeutic application of Colofac is primarily for IBS and spasms, some practitioners may explore off-label uses. For instance, certain clinicians report success using Colofac for functional dyspepsia or as an adjunct in complex gastrointestinal cases, although these uses are not officially endorsed and require careful patient assessment.

Key Clinical Findings

Recent studies conducted between 2022 and 2025 in both Australian and international settings highlight the efficacy and safety of mebeverine in treating IBS. A clinical trial assessing its impact on patient-reported outcomes indicated significant reductions in abdominal pain and discomfort. Furthermore, findings showed a favourable safety profile, with most participants experiencing only mild side effects. This positions mebeverine as a reliable option for managing gastrointestinal symptoms in diverse patient populations.

Alternatives Matrix

When managing IBS and gastrointestinal symptoms, Colofac offers unique benefits and some drawbacks compared to its alternatives. Advantages include its targeted action, which minimises systemic side effects. However, it may take longer to show efficacy compared to faster-acting antispasmodics. Patients sensitive to anticholinergic side effects often prefer Colofac for its specific action.

Common Questions

Common questions from patients about Colofac centre around its dosage, safety, and potential side effects. Typically, adults are advised to take 135 mg tablets three times daily or 200 mg modified-release capsules twice daily. Patients often express concern over side effects, which may include mild dizziness or gastrointestinal upset but generally decrease over time.

Patients often inquire about the medication's safety for long-term use. Colofac is considered non-habit forming and can be used under medical supervision for extended periods. Nevertheless, it is vital to avoid using it for acute abdominal pain without medical advice.

Suggested Visual Content

Infographics can help convey the essential details regarding Colofac to the public effectively.

Proposed graphics include:

• A comparison chart that outlines the PBS pricing of Colofac relative to similar medications.
• A pharmacy network map indicating various locations throughout Australia that stock Colofac, making it easier for patients to find the medication they need.

Registration & Regulation

The TGA (Therapeutic Goods Administration) plays a crucial role in regulating Colofac in Australia. By ensuring that medications undergo rigorous evaluation, the TGA guarantees both the safety and efficacy of Colofac before it reaches consumers. For a medication like Mebeverine, understanding its approval status is essential to ensure that it aligns with health standards.

Colofac is available as a prescription-only medicine and is registered with the TGA for therapeutic use. This means that only qualified healthcare providers can prescribe it, ensuring proper medical supervision.

As for the PBS (Pharmaceutical Benefits Scheme), there are specific conditions under which Colofac can be subsidised. Patients may be eligible for subsidy if they meet particular clinical criteria related to their diagnosis, specifically conditions like irritable bowel syndrome (IBS). It’s advisable for patients to consult with their healthcare providers to understand whether they qualify for this subsidy and how it can help offset costs.

Storage & Handling

Given Australia's diverse climate, storing Colofac effectively is essential for maintaining its quality.

• Household storage: Colofac should be kept below 25°C, away from light and moisture. This is vital to preserve the active ingredient's stability.
• Especially during summer months with heightened humidity, keeping the medication in a cool, dry place—like a medicine cabinet away from direct sunlight—ensures its efficacy.

For pharmacies, following cold-chain handling protocols when transporting Colofac is paramount. Medications must be stored in original blister packaging and kept under controlled temperatures during transit. This practice not only preserves the medication's integrity but also complies with stringent regulations regarding pharmaceutical products.

Guidelines for Proper Use

When it comes to counselling patients about Colofac, Australian pharmacists tend to adopt a structured and supportive approach. They typically review the patient's medical history, explain the proper dosage (135 mg three times daily for standard tablets, for instance), and highlight potential side effects.

In terms of overarching guidance, health authorities emphasise that patients using Colofac should monitor their symptoms closely. If symptoms of IBS persist after two weeks, a follow-up consultation is advised. This guidance helps patients understand how to use Colofac effectively, ensuring they know what to watch for in terms of side effects or a lack of symptom relief.

Importantly, patients are informed that Colofac is typically well-tolerated, offering relief from abdominal pain and cramps. Advice extends to the appropriate use for constipation as well, stressing its effectiveness in managing symptoms without systemic anticholinergic effects, making it suitable for long-term management.